Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX) declared a quarterly dividend of $1.05 per share, a 1.0% increase from the prior quarter. The dividend is payable on December 31, 2025 to holders of record on December 8, 2025.

The company set an indicated annual dividend rate for fiscal year 2026 of $4.20 per share. This marks the 54th consecutive fiscal year BD has raised its dividend, maintaining its membership in the S&P 500 Dividend Aristocrats Index. Management linked the increase to confidence in BD's long-term outlook during execution of the Waters RMT transaction.

BD (NYSE: BDX) announced on November 4, 2025 that the AGILITY IDE study has achieved full enrollment of the common and external iliac artery cohort (n=118) for the Revello™ Vascular Covered Stent in peripheral artery disease (PAD).

The multi-center, prospective AGILITY study (NCT06111469) is enrolling at up to 45 sites across the United States, Europe, Australia and New Zealand and includes a second cohort for superficial femoral and proximal popliteal arteries (n=223) with enrollment ongoing. The milestone was announced during a late-breaking presentation at VIVA 2025 by Dr. Sean Lyden.

BD (NYSE: BDX) received FDA 510(k) clearance and CE-IVDR/CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System on Nov 3, 2025.

The molecular panels use PCR on the BD COR system to detect a broad range of GI bacterial pathogens from a single stool swab and run on a high-throughput automated system with capacity for nearly 1,650 tests and up to 1,000 sample results in 24 hours, plus up to 7 hours walk-away time and room-temperature reagents.

BD (NYSE: BDX) announced an IVDR-certified, dry self-collection swab and fully automated lab workflow for HPV testing outside the United States on Oct 22, 2025. The solution enables safe at-home sample collection without liquids, supports mailing to labs, and requires no manual sample preparation for clinical laboratory technologists when used with the BD COR™ System.

Key technical points:

• 30-day dry sample stability, including up to 5 days at 45°C and 4 freeze/thaw cycles
• Onboard Rehydration Technology to eliminate manual prep
• Barcode-driven unified workflow and internal cellular control for specimen integrity

The product is expected to be commercially available across IVDR-recognized markets in the coming months.

BD (NYSE: BDX) on Oct 20, 2025 launched the BD Incada™ Connected Care Platform, an AI-enabled, AWS-based cloud platform that unifies BD device data into a single ecosystem and supports analytics for nearly 3 million smart connected BD devices.

At the same time BD introduced the next-generation BD Pyxis™ Pro Dispensing Solution, a stackable automated medication dispenser that adds capacity (up to 538 multi-access or 98 secure pockets) in a similar footprint, and adds security, RFID badge scanning, wireless barcode scanning and illuminated bins.

The combined offering emphasizes enterprise-wide medication visibility, natural-language analytics, customizable dashboards, and secure cloud storage aimed at reducing medication waste, improving labor efficiency, and speeding point-of-care access. BD notes the Pyxis system processes about 9.8 million transactions per day.

BD (NYSE: BDX) celebrated 65 years of manufacturing at its Broken Bow, Nebraska facility on Oct. 16, 2025. The site opened Oct. 18, 1960 and has grown from a 13,753-square-foot plant with 20 associates to a 310,000-square-foot facility employing nearly 600 associates.

Broken Bow is described as the world's largest manufacturer of BD Vacutainer® tubes, producing billions of tubes and other collection products annually. BD reports more than $50 million invested in Nebraska since 2020 and announced a separate >$35 million investment and 50 jobs at its Columbus facility. BD operates 30+ U.S. sites with ~10,000 employees.

BD (NYSE: BDX) announced a CFO transition: Chris DelOrefice will depart effective Dec. 5, 2025 and Vitor Roque will become interim CFO. The company provided preliminary unaudited results for the period ended Sept. 30, 2025, including Q4 revenue ≈ $5.9 billion (reported +8.3%, currency‑neutral +7.0%, organic +3.9%) and full‑year revenue ≈ $21.8 billion (reported +8.2%, currency‑neutral +7.7%, organic +2.9%).

BD expects fiscal 2025 adjusted diluted EPS to be at or above the midpoint of prior guidance, and will discuss results on an audio webcast Nov. 6, 2025. Preliminary figures are unaudited and subject to change.

BD (NYSE: BDX) said management will host an audio webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to discuss fourth-quarter and full-year fiscal 2025 results (fiscal year ended September 30, 2025) and provide an operations and strategy update.

The company will issue a news release and presentation materials with summary financial information prior to the call. The live webcast and a replay will be available at www.bd.com/investors.

BD (NYSE: BDX) announced enrollment of the first patient in the XTRACT™ Registry on September 29, 2025, a prospective, multi-center, single-arm post-market study to evaluate real-world performance of the Rotarex™ Catheter System for peripheral artery disease (PAD).

The registry plans up to 600 patients across as many as 100 U.S. sites with follow-ups at 30 days, 6 months, and 12 months to assess safety and effectiveness. The Rotarex catheter offers combined atherectomy and thrombectomy mechanisms to remove plaque and thrombus. BD said the registry will generate real-world evidence to inform clinical decision-making and treatment strategies for PAD.